Sant Pau researchers agree to alleviate diabetic neuropatiia

Researchers at the Institut de Recerca de Sant Pau, the Institut de Neurociències de la Universitat Autònoma de Barcelona and the CIBER de Diabetis i Malalties Metabòliques Associades (CIBERDEM) have succeeded in inhibiting neuropathic pain in diabetic ratolins by administering a class of molecules with the property of releasing carbon monoxide. Its effectiveness suggests a great therapeutic potential of this drug for the treatment of diabetic neuropatiia in patients.

Neuropathic pain is one of the main complications of diabetes mellitus and it is estimated that approximately one out of every three diabetic patients have it. Although its physiopathological basis is not known exactly, recent evidence suggests that diabetes promotes neuroinflammation and thus plays a key role in the manifestation of signs of chronic pain in diabetics.
Researchers point to “the use of carbon monoxide, based on its anti-inflammatory properties, for the treatment and alleugeriment of neuropathic pain”. However, “its use requires a galenic formulation that allows for the dispensation and/or alliberament control of this carbon monoxide from nontoxic agents,” he says.

A new study, published in PLoS One, has demonstrated the effectiveness of the drug Corm-2, based on carbon monoxide alliberator molecules, for the treatment of diabetic neuropatias in ratolins with type 1 diabetes. The researchers, led by Josep Julve, from the group Bases metabòliques del risc cardiovascular and Olga Pol, from the Molecular Neuropharmacology group, both from the Sant Pau Research Institute, have identified the molecular mechanisms involved in the antioxidative and anti-inflammatory effect through which the drug exerts its action.

Paper of Corm-2 in the treatment of diabetic neuropatiia
Carbon monoxide release molecules, called Corm (Carbon Monoxide-Releasing Molecules), are erected as a valid alternative to the use of therapies based on the inhalation of this gas, with equally favorable properties in different experimental models of inflammation, but less perilloses. In particular, the Corm-2 drug, one of the most frequently employed Corm representatives, has been evaluated satisfactorily by the Group led by Olga Pol in experimental models of inflammatory and neuropathic pain.
Ara, the researchers have studied its effectiveness in remission of neuropathic pain in a chronic and proinflammatory condition such as diabetes: “In this work we want to evaluate the anti-inflammatory / antioxidant effect exercised by Corm-2 molecules and their potential analgesic effect on neuropathic pain associated with type 1 diabetes mellitus,” explains Olga Pol.
“The reports conclude that the inhibition of neuropathic pain produced by the administration of Corm-2 is related to favourable changes in the expression of neuroinflammatory markers and oxidative stress in diabetic mice”, states Josep Julve.

Although the improvement in neuropatia observed in diabetic ratolins treated with Corm-2, this work also showed potential non-beneficial effects as its administration also produced an elevation, albeit moderate, in the circulating levels of cholesterol. “The favourable effects shown for Corm-2 reinforce the need to continue researching in this line of work, proving the effect of galenic formulae with the same efficiency without secondary effects in the desitjats”, says the first signant of the work, Karen Alejandra Méndez Lara.

“The results make possible new therapeutic possibilities for the use of this class of drugs in the handling of neuroinflammatory based complications in diabetic patients”, concluded the researchers.

* Researchers José Luis Sánchez-Quesada, Núria Farré, Sheila Ruiz-González, Jesús M. Martín-Camps, Enrique Lerma, Edgar Zapico and Francisco Blanco-Vaca from CIBERDEM, from the Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau-IIB Sant Pau and director of the Servei de Bioquímica i el Servei de Patologia Digestiva de l’Hospital de la Santa Creu i Sant Pau de Barcelona have also taken part in the study, as have Núria Farré, Sheila Ruiz-González, Jesús M. Martín-Camps, Enrique Lerma, Edgar Zapico and Francisco Blanco-Vaca from CIBERDEM, from the Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau-IIB Sant Pau and director of the Servei de Patologia Digestiva from the Hospital de la Santa Creu i Sant Pau in Barcelona.

Reference article:
Administration of Corm-2 diabetic neuropathy inhibits but does not reduce dyslipidemia in diabetic mice. Méndez-Lara KA, Sants D, Farré N, Ruiz-Nogales S, Leánez S, Sánchez-Quesada JL, Zapico I, Lerma E, Escolà-Gil JC, Blanc-Vaca F, Martín-Camps JM, Julve J, Pol O . PLoS One. 2018 October 4; 13 (10): e0204841.DOI: 10.1371 / journal.pone.0204841

Translated with

edifici Ir web

This website uses cookies to improve the browsing experience and perform analytical tasks. If you continue browsing, we understand that you agree our cookies policy. More information